250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics, USA. HRG reviewed 28 products in the health category, 213 items in the wellness sector and 31 items in the beauty ...

250 mg/125 mg (OTC) market achieved annual sales of approximately $84.1 million. Glenmark’s current portfolio consists of 195 products authorized for distribution in the U.S. marketplace and 52 ...

Drug makers Aurobindo Pharma, Glenmark and Zydus are recalling products in the US market due to manufacturing issues, according to the US health regulator. As per the latest Enforcement Report of ...

Glenmark’s current portfolio includes 201 products authorized for distribution in the US marketplace ... having a presence across branded, generics, and OTC segments; with a focus on therapeutic areas ...